|
Sep 30
|
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference
|
|
Sep 9
|
Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
|
|
Sep 5
|
Akero Therapeutics, Inc. (AKRO): This Small-Cap Healthcare Stock Is A Good Buy Right Now
|
|
Aug 28
|
Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
|
|
Jul 16
|
Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade
|
|
Jun 11
|
Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
|
|
May 13
|
Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ...
|
|
May 10
|
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 8
|
Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference
|
|
Apr 30
|
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
|
|
Mar 20
|
Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks
|
|
Mar 18
|
Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That
|
|
Mar 15
|
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
|
|
Mar 14
|
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
|
|
Mar 8
|
Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
|
|
Mar 7
|
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
|
|
Mar 7
|
President and CEO Andrew Cheng Sells 75,000 Shares of Akero Therapeutics Inc (AKRO)
|
|
Mar 6
|
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
|
|
Mar 5
|
Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
|
|
Mar 4
|
Akero Therapeutics Announces Proposed Public Offering of Common Stock
|